RT Journal Article
SR Electronic
T1 Wastewater-based surveillance is an efficient monitoring tool for tracking influenza A virus in the community
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.08.28.23294723
DO 10.1101/2023.08.28.23294723
A1 Kirsi-Maarit, Lehto
A1 Rafiqul, Hyder
A1 Annika, Länsivaara
A1 Oskari, Luomala
A1 Anssi, Lipponen
A1 Hokajärvi, Anna-Maria
A1 Annamari, Heikinheimo
A1 Tarja, Pitkänen
A1 Sami, Oikarinen
A1 WastPan Study Group
YR 2023
UL http://medrxiv.org/content/early/2023/08/28/2023.08.28.23294723.abstract
AB Around the world, influenza A virus has caused severe pandemics, and the risk of future pandemics remains high. Currently, influenza A virus surveillance is based on the clinical diagnosis and reporting of disease cases. In this study, we apply wastewater-based surveillance to monitor the incidence of the influenza A virus at the population level. We report incidence data of the influenza A virus in 10 wastewater treatment plant catchment areas covering 40% of the Finnish population. Altogether, 141 monthly composite influent wastewater samples (collected between April 2020 and May 2021) were analysed from supernatant fraction using influenza A virus specific RT-qPCR method. During the study period, an influenza A virus epidemic occurred in two waves in Finland. This study shows that the influenza A virus can be detected from the supernatant fraction of 24 h composite influent wastewater samples. The influenza A virus gene copy number in wastewater correlated with the number of confirmed disease cases in the Finnish National Infectious Diseases Register. The Kendall’s τ correlation strength was over 0.600 in all wastewater treatment plants, save for one, which was 0.459. The strongest correlations were 0.761 and 0.833. Wastewater-based surveillance of the influenza A virus is an unbiased method and cost-efficiently reflects the circulation of the virus in the entire population. Thus, wastewater monitoring complements the available, but often too sparse, information from individual testing and improves health care and public health preparedness for influenza A virus pandemics.Competing Interest StatementSami Oikarinen reports a relationship with Greenseq Ltd that includes: board membership. Kirsi-Maarit Lehto reports a relationship with Greenseq Ltd that includes: board membership and travel reimbursement.Funding StatementThis work was funded by the Academy of Finland with grant number 339416.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors